Another MDM2 inhibitor, APG-115, can enhance antitumor immunity in the TME by increasing M1 macrophage polarization and T-cell activation and the anti-PD-1-mediated antitumor effect on mouse models of cancer immunotherapy [166]. The gene discussed is PDCD1; the disease is cancer.